Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6403564B1 · kind B1 · utility
55Cited by
3References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 1999 |
| Grant date | Jun 11, 2002 |
| Priority date | — |
| Expiry date | Oct 14, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/212
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula I and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.